<DOC>
	<DOCNO>NCT03084471</DOCNO>
	<brief_summary>This open-label , multi-center , study determine safety fix dos durvalumab 1500 mg tremelimumab 75mg combination therapy durvalumab 1500 mg monotherapy participant advance solid malignancy . The core study ( tumor specific module ) consist screen period , treatment period , safety follow-up period survival follow-up period . The study plan determine short long term safety include evaluation nature toxicity ( AEs , adverse event special interest ( AESIs ) , SAEs , immune-mediated adverse event [ imAEs ] ) , intervention / treatment , outcomes treatment . Please note : initially study recruit patient urothelial non-urothelial urinary tract cancer .</brief_summary>
	<brief_title>An Open-Label , Multi-Centre , Study Assess Safety Fixed-Dose Durvalumab + Tremelimumab Combination Therapy Durvalumab Monotherapy Advanced Solid Malignancies .</brief_title>
	<detailed_description>Participants receive either durvalumab tremelimumab ( combination therapy ) durvalumab ( monotherapy ) depend tumor specific module . Please note : initially study recruit patient urothelial non-urothelial urinary tract cancer .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Participants must fulfill follow inclusion criterion along protocol/ module specific inclusion criterion : 1 . Age ≥ 18 year time screen . 2 . Disease amendable curative surgery 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status define specific module . 4 . No prior exposure antiPD1or antiPDL1 . 6 ) Adequate organ marrow function independent transfusion least 7 day prior screen independent growth factor support least 14 day prior screen . For inclusion Module A study participant fulfill follow criterion : 1 . Histologically cytologicaly confirm locally advanced metastatic urothelial nonurothelial carcinoma urinary tract ( include urinary bladder , ureter , urethra renal pelvis ) 2 . Disease progress least one previous platinum nonplatinum base chemotherapy , either metastatic disease progressive disease le 12 month adjuvant neoadjuvant chemotherapy 3 . ECOG performance status 02 Participants include study meet follow along protocol/ module specify exclusion criterion : 1 . Involvement plan and/or conduct study . 2 . Concurrent enrollment another clinical study . 3 . Any concurrent chemotherapy , investigational agent , biologic , hormonal therapy cancer treatment . 4 . Local treatment isolate lesion palliative intent acceptable ( e.g. , local surgery radiotherapy ) . 5 . Receipt investigational anticancer therapy within 28 day 5 halflives , whichever short , prior first dose study treatment . 6 . Radiotherapy treatment 30 % bone marrow wide field radiation within 4 week first dose study drug . 7 . Major surgical procedure ( defined Investigator ) within 28 day prior first dose IP . 8 . History allogenic organ transplantation . 9 . Uncontrolled intercurrent illness . 10 . History leptomeningeal carcinomatosis 11 . Has untreated central nervous system ( CNS ) metastases and/or carcinomatous meningitis identify either baseline brain imaging ( please refer RECIST detail image modality ) obtain screen period identify prior signing ICF . 12 . History active primary immunodeficiency . 13 . Active infection include tuberculosis , hepatitis B , hepatitis C , human immunodeficiency virus ( positive HIV ½ antibody ) . 14 . Current prior use immunosuppressive medication within 14 day first dose durvalumab tremelimumab . 15 . Active prior document autoimmune inflammatory disorder ( include inflammatory bowel disease [ e.g. , colitis Crohn 's disease ] , diverticulitis [ exception diverticulosis ] , systemic lupus erythematosus , Sarcoidosis syndrome , Wegener syndrome [ granulomatosis polyangiitis , Graves ' disease , rheumatoid arthritis , hypophysitis , uveitis , etc ] ) . The following exception criterion : Participants vitiligo alopecia Participants hypothyroidism ( e.g. , follow Hashimoto syndrome ) stable hormone replacement Any chronic skin condition require systemic therapy Participants without active disease last 5 year may include consultation study physician Participants celiac disease control diet alone 16 . Receipt live attenuate vaccine within 30 day prior first dose IP . 17 . Known allergy hypersensitivity study drug ( ) 18 . Any unresolved NCI CTCAE Grade ≥2 toxicities prior anticancer therapy exception vitiligo , alopecia , laboratory value define inclusion criterion . 19 . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Programmed death ligand 1 ( PD-L1 )</keyword>
	<keyword>Cytotoxic T-lymphocyte antigen-4 ( CTLA-4 )</keyword>
	<keyword>Durvalumab combination tremelimumab</keyword>
</DOC>